Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 14 · below the Ichimoku cloud · RSI 54 · MACD above its signal · 8% above its 52-week low
| 9.90 | 52-week high | +31.30% |
| 7.99 | Previous month high | +5.97% |
| 7.76 | R3 (classic) | +2.91% |
| 7.66 | R2 (classic) | +1.59% |
| 7.60 | R1 (classic) | +0.79% |
| 7.57 | Previous week high | +0.40% |
| 7.56 | Previous day high | +0.26% |
| 7.54 | Price now | |
| 7.50 | Pivot | −0.53% |
| 7.44 | S1 (classic) | −1.32% |
| 7.40 | Previous day low | −1.86% |
| 7.34 | S2 (classic) | −2.65% |
| 7.28 | S3 (classic) | −3.44% |
| 7.28 | Previous week low | −3.45% |
| 7.15 | Previous month low | −5.17% |
| 6.96 | 52-week low | −7.69% |
None of the 29 investors followed here reported a position in GRFS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GRFS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.1 | -1.6 | -11.9 | 2.7 | -4.7 | -9.8 | 11.2 | -1.9 | -5.3 | 3.1 | −19.4% | ||
| 2025 | -7.4 | 22.5 | -15.8 | -2.3 | 19.6 | 8.8 | 18.4 | -6.8 | -0.1 | -5.9 | -5.5 | 5.6 | +25.7% |
| 2024 | -30.4 | -6.6 | -11.1 | -3.7 | 11.4 | -11.9 | 18.4 | 25.0 | -4.9 | -2.1 | -19.6 | 6.4 | −35.6% |
| 2023 | 7.2 | -4.9 | -14.9 | 1.2 | 10.5 | 11.2 | 19.1 | -13.2 | -3.5 | -11.5 | 19.8 | 19.3 | +36.0% |
| 2022 | 4.5 | 5.3 | -5.5 | -8.1 | 20.0 | -7.8 | -25.3 | -12.5 | -20.7 | 2.4 | 29.2 | 4.3 | −24.3% |
| 2021 | -4.1 | -8.0 | 6.3 | 2.1 | -0.9 | -0.8 | -12.3 | -4.7 | 0.8 | -10.3 | -18.2 | 4.7 | −39.1% |
| 2020 | -2.4 | -5.8 | -5.9 | 0.8 | -6.7 | -3.6 | 3.5 | -15.1 | 8.2 | -2.1 | 9.1 | -0.5 | −20.8% |
| 2019 | 1.4 | 3.5 | 4.3 | -4.8 | -8.1 | 20.0 | 7.9 | -6.4 | -5.9 | 9.3 | 4.4 | 1.8 | +26.9% |
| 2018 | 8.4 | -12.3 | -2.8 | -4.2 | 7.4 | -1.5 | -3.3 | 4.7 | -1.7 | -4.4 | -3.4 | -6.9 | −19.9% |
| 2017 | 5.8 | 2.4 | 8.5 | 15.0 | -1.2 | -1.5 | -0.9 | -1.4 | 6.0 | 8.0 | -3.8 | 0.7 | +42.6% |
| 2016 | -10.4 | 7.4 | -0.8 | 1.6 | 5.2 | 0.8 | 1.6 | -6.1 | 0.4 | -10.5 | 9.4 | 2.8 | −0.8% |
| 2015 | 1.4 | -4.9 | 0.2 | -3.0 | -0.0 | -2.6 | 4.8 | -6.7 | 0.4 | 14.5 | -0.2 | -6.8 | −4.7% |
| 2014 | 9.7 | 6.2 | -1.9 | -0.6 | 1.4 | 5.8 | -16.8 | 9.5 | -12.5 | 0.7 | 5.2 | -8.7 | −5.9% |
| 2013 | 2.6 | 7.8 | 1.2 | 7.7 | -12.7 | 4.5 | 11.4 | -4.6 | -0.0 | -0.4 | 13.9 | 5.2 | +39.3% |
| 2012 | 14.8 | 12.0 | 8.4 | 22.7 | -10.5 | 13.3 | 16.2 | -7.8 | 11.0 | 10.2 | -3.1 | 11.6 | +146.2% |
| 2011 | 6.1 | -13.7 | -7.1 | 0.3 | -13.7 | 0.0 | −26.4% |
No insider transactions reported for GRFS.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Buy / hold / sell counts